Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.

@article{Castagnoli2014ActivatedDH,
  title={Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.},
  author={Lorenzo Castagnoli and Manuela Iezzi and Gaia Cristina Ghedini and Valentina Ciravolo and Giulia Marzano and Alessia Lamolinara and Roberta Zappasodi and Patrizia Gasparini and Manuela Campiglio and Augusto Amici and Claudia Chiodoni and Arianna Palladini and Pier Luigi Lollini and Tiziana Triulzi and Sylvie M{\'e}nard and Patrizia Nanni and Elda Tagliabue and Serenella M Pupa},
  journal={Cancer research},
  year={2014},
  volume={74 21},
  pages={6248-59}
}
A splice isoform of the HER2 receptor that lacks exon 16 (d16HER2) is expressed in many HER2-positive breast tumors, where it has been linked with resistance to the HER2-targeting antibody trastuzumab, but the impact of d16HER2 on tumor pathobiology and therapeutic response remains uncertain. Here, we provide genetic evidence in transgenic mice that expression of d16HER2 is sufficient to accelerate mammary tumorigenesis and improve the response to trastuzumab. A comparative analysis of effector… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
9 Citations
45 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Epub;%2013 Jul 1.:973584

  • R Zagozdzon, WM Gallagher, J. Crown
  • 2013

Truncated HER 2 : implications for HER 2targeted therapeutics

  • R Zagozdzon, WM Gallagher, J Crown
  • Drug Discov Today
  • 2013

Activity and resistance mechanisms of trastuzumab in different clinical settings

  • E Tagliabue, M Campiglio, SM Pupa, S Ménard, A. Balsari
  • Cancer Treat Rev 2012;38:212-7 doi: 10.1016/j…
  • 2011

Similar Papers

Loading similar papers…